Clinical Trials Browser

Phase 2 × Lymphoma × camrelizumab × Clear all

NCT05320081 2022-04-11

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Phase 2 Unknown

Lymphoma, Recurrence